Oncotherapeutics, an oncology specific Contract Research Organization (CRO) specializing in the oversight and management of clinical trials for cancer, will present final results from a multicenter clinical trial at the American Society of Hematology Annual Meeting in San Diego, California on December 10-13 , 2011.

The title of the poster is: Bendamustine Combined with Bortezomib has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study.

With expertise in phase I-IV clinical trials and pharmacokinetic studies, Oncotherapeutics offers a wide array of services that are custom tailored to meet the needs of pharmaceutical and biotech sponsors. Oncotherapeutics is currently recruiting for the following studies:

 A Phase I/II Study of Carfilzomib as a Replacement for Bortezomib for Multiple Myeloma Patients Failing Bortezomib-Containing Regimens

 A Phase III Study of Armodafinil for the Treatment of Cancer-Related Fatigue for Patients with Multiple Myeloma.

For more information on these trials, please visit www.clinicaltrials.gov. site whois .